Research Analysts Set Expectations for IOVA FY2026 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities research analysts at Zacks Research upped their FY2026 earnings per share estimates for shares of Iovance Biotherapeutics in a research report issued on Wednesday, September 30th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.55) for the year, up from their prior estimate of ($0.56). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.46) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.39) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.01) EPS, Q3 2028 earnings at $0.00 EPS and FY2028 earnings at ($0.03) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The business had revenue of $99.31 million during the quarter, compared to analyst estimates of $87.83 million. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. The company’s revenue was up 65.7% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. Citizens Jmp lifted their target price on Iovance Biotherapeutics from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Barclays increased their price objective on Iovance Biotherapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. HC Wainwright upped their price objective on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Tuesday. Finally, Mizuho raised their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.40.

Iovance Biotherapeutics Trading Down 4.0%

NASDAQ IOVA opened at $14.23 on Friday. The stock’s 50-day moving average price is $8.16 and its two-hundred day moving average price is $5.42. Iovance Biotherapeutics has a 1 year low of $1.76 and a 1 year high of $15.30. The company has a market cap of $6.45 billion, a PE ratio of -19.49 and a beta of 0.75.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IOVA. BlackRock Inc. acquired a new stake in shares of Iovance Biotherapeutics during the second quarter worth $153,744,000. Palo Alto Investors LP bought a new stake in Iovance Biotherapeutics during the second quarter worth about $22,032,229. Bank of America Corp DE bought a new position in shares of Iovance Biotherapeutics in the second quarter valued at $20,773,000. Knott David M Jr acquired a new position in shares of Iovance Biotherapeutics during the 1st quarter worth about $5,616,000. Finally, Rice Hall James & Associates LLC bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth approximately $6,406,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised its 2026 revenue outlook to $410 million-$420 million, citing strong demand for its marketed therapies. The improved guidance was the primary catalyst behind the recent rally and signals better-than-expected commercial momentum. IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
• Positive Sentiment: Analysts are becoming more optimistic about IOVA’s earnings trajectory. Zacks Research raised multiple quarterly forecasts, lifted its FY2026 estimate to a loss of $0.55 per share from $0.56, and improved its FY2027 and FY2028 forecasts to losses of $0.39 and $0.03, respectively. HC Wainwright also raised estimates, maintains a Buy rating, and has a $20 price target. Wells Fargo raised its target to $18 and assigned an Overweight rating. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
• Neutral Sentiment: Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer. His global drug-development experience in T-cell therapies could support pipeline execution, although the appointment is unlikely to materially change near-term financial results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
• Negative Sentiment: Despite improving forecasts, IOVA remains unprofitable, with analysts still projecting losses through 2028. After the stock’s rapid advance and move near its 12-month high, investors may be taking profits, while the elevated expectations leave the shares vulnerable if revenue growth or commercialization momentum slows.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.